Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Axsome Therapeutics, Inc.NASDAQ: AXSM

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $51.31M (cash outflow) rose 7.0% year over year, ahead of the -22.4% change in trailing-twelve-month net income. Sequentially, it fell 20.5% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.

Context

  • Net income amounted to 28.7% of revenue in FY2025, down 45.8 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of -$127.69M (-30.3%) for the fiscal year ending Dec 2026, a step up from the -36.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$51.31M-20.5% QoQ
Last fiscal yearDec 2025
-$183.17M-36.2% YoY
LTMJun 2026
-$191.64M-22.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.0%-29.6%-36.5 pp
1 year-36.2%-30.3%+5.9 pp
3-year CAGR-0.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(183.17M) USD
Year-over-year change
+36.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's LTM Jun 2026 net income of $191.64M is the 8th largest of the 11 companies compared; the peer median is $279.94M.
  • Its year-over-year change of -22.4% is the 10th highest of 11, against a peer median of +33.1%.
  • Net income amounts to 24.7% of revenue for AXSM, versus a peer median of 19.1%.
AXSM Competitors Peer median
Net Income for AXSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$901.05M +144.5%+16.7%19.1%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$702.5M +64.1%+45.8%19.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$511.45M +6.8%+16.3%14191.2%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$428.73M +40.0%+40.3%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$359.43M +31.6%+12.3%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$337.48M +100.8%+47.9%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M -13.8%+21.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$191.64M -22.4%-0.7%24.7%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$144.33M -323.8%—17.4%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.28M +34.6%+118.7%536.4%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$39.95M -14.1%-1.1%—
Peer median (excluding AXSM) $279.94M+33.1%+21.9%19.1%

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(130.4M)(187.13M)(239.24M)(287.22M)(183.17M)
Depreciation & Amortization76K4.4M6.83M7.96M9.06M
Deferred Income Tax00000
Stock-Based Compensation20.8M37.73M62.62M85.22M93.75M
Change in Working Capital324K23.67M(28.39M)33.9M(22.52M)
Accounts Receivables0(37.7M)(57.12M)(47.18M)(82.46M)
Inventory(6K)(5.28M)(8.16M)(2.44M)(15.67M)
Accounts Payables(355K)25.46M2.07M31.32M(6.46M)
Other Working Capital685K41.19M34.81M52.2M82.07M
Other Non-Cash Items974K4.83M53.1M31.73M9.48M
Operating Cash Flow(108.23M)(116.51M)(145.08M)(128.41M)(93.41M)
Capital Expenditures(308K)(702K)(582K)(270K)(480K)
Acquisitions (Net)0(53M)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(308K)(53.7M)(582K)(270K)(480K)
Debt Repayment045M85M(990K)(7.75M)
Common Stock Issued7.44M243.76M258.75M40.78M126.27M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.69M(4.18M)(12.74M)18.05M(17.05M)
Financing Cash Flow11.13M284.58M331.01M57.84M101.47M
Effect of Forex Changes00000
Net Change in Cash(97.4M)114.37M185.35M(70.84M)7.58M
Free Cash Flow(108.53M)(117.21M)(145.66M)(128.68M)(93.89M)

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.